Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alagille Syndrome: full-pipeline trial registry
3 of 4 indexed Alagille Syndrome trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Alagille Syndrome: 4 US clinical trials tracked, 3 recruiting.
Alagille Syndrome is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Mirum Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition alagille-syndrome
OPEN 3 | RECR 75% | LATE 1 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Alagille Syndrome lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alagille Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alagille Syndrome is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
Mirum Pharmaceuticals
NCT06193928
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Albireo, an Ipsen Company
NCT05035030
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
Ipsen
NCT06850038
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
Mirum Pharmaceuticals
NCT02117713
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Alagille Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alagille Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alagille Syndrome page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Alagille Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mirum Pharmaceuticals sponsors the most Alagille Syndrome trials on record, review their full trial history before evaluating a specific study. See Mirum Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alagille Syndrome condition card totals 4 registered trials; most-linked intervention LUM001 (Maralixibat); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.